Verastem, Inc. - B (09887.HK): The first patient in the LBL-024 trial for platinum-resistant ovarian cancer in stages IB/II received treatment. (Note: The translation of "-B" is "Verastem, Inc. - B", and "IB/II" translates to "platinum-resistant ovarian cancer in stages IB/II trial". )

Financial news app Zhitong announced that Whiboy-B (09887.HK) has released a statement evaluating the first patient in the phase Ib/II clinical trial of Opatazumab monotherapy (PD-L1/4-1BB bispecific antibody LBL-024) for the treatment of platinum-resistant ovarian cancer has been successfully treated.